Journal
COUNTERMEASURES AGAINST CHEMICAL THREATS
Volume 1374, Issue -, Pages 202-209Publisher
BLACKWELL SCIENCE PUBL
DOI: 10.1111/nyas.13114
Keywords
cyanide antidote; 3-mercaptopyruvate sulfurtransferase; 3-MST; sulfanegen; cyanide poisoning
Categories
Funding
- NINDS NIH HHS [U01 NS058087] Funding Source: Medline
Ask authors/readers for more resources
Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our laboratory is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. This article summarizes the journey from concept to clinical leads for this promising cyanide antidote.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available